AACR 2022 Poster: Pre-clinical development of CAR Monocytes (CAR Mono) for solid tumor immunotherapy July 14, 2022 View
AACR 2022 Poster: Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy July 14, 2022 View
ASCO 2022 Poster: A Phase 1, First-In-Human (FIH) Study of the Anti-HER2 CAR Macrophage CT-0508 in Participants with HER2 Overexpressing Solid Tumors July 14, 2022 View
SITC 2021 Poster: Development and Characterization of Chimeric Antigen Receptor Monocytes (CAR Mono), a Novel Cell Therapy Platform for Solid Tumor Immunotherapy November 30, 2021 View
SITC 2021 Poster: SIRP⍺-Deficient CAR-Macrophages Exhibit Enhanced Anti-Tumor Function and Bypass the CD47 Immune Checkpoint November 30, 2021 View
SITC 2021 Poster: Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD-1 blockade in immunocompetent mouse models of HER2+ solid tumors November 30, 2021 View
SITC 2021 Poster: LBA (951): A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data November 30, 2021 View
AACR 2021: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models April 9, 2021 View
AACR 2021 Poster: Chimeric antigen receptor macrophages (CAR-M) induce antitumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models April 9, 2021 View
SITC 2020 Poster: Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD-1 blockade in immunocompetent mouse models of HER2+ solid tumors November 10, 2020 View
SITC 2020 Poster: Development of an M1-Polarized, Non-Viral CARMacrophage (CAR-M) Platform for Cancer Immunotherapy November 10, 2020 View
